antibiotics

Achaogen’s bankruptcy and going-out-of-business sale offer a grim cautionary tale for the future of antibiotic development
Achaogen’s bankruptcy and going-out-of-business sale offer a grim cautionary tale for the future of antibiotic development
Endpoints
Achaogen
bankruptcy
antibiotics
drug development
Flag link:
Small biotech the ‘true engine’ of antibiotic innovation, as pharma ‘spews nonsense’ on its R&D: Jim O'Neill
Small biotech the ‘true engine’ of antibiotic innovation, as pharma ‘spews nonsense’ on its R&D: Jim O'Neill
Fierce Biotech
R&D
antibiotics
antibiotic resistance
Flag link:
Throwing in the towel, troubled antibiotic maker Aradigm files for Chapter 11
Throwing in the towel, troubled antibiotic maker Aradigm files for Chapter 11
Endpoints
Aradigm
antibiotics
bankruptcy
Apulmiq
Flag link:
The antibiotics R&D effort is broken. Here's one market solution that might fix it
The antibiotics R&D effort is broken. Here's one market solution that might fix it
Endpoints
R&D
antibiotics
Flag link:
Novartis shares data on discontinued antibiotic research
Novartis shares data on discontinued antibiotic research
BioCentury
Novartis
R&D
antibiotics
Flag link:
Genentech develop antibiotic with potential to lead to new class of antibiotics
Genentech develop antibiotic with potential to lead to new class of antibiotics
Pharmaforum
Genentech
G07750
antibiotics
drug development
antibiotic resistance
Flag link:
Eisai, Takeda and GARDP hunt for new antibiotics
Eisai, Takeda and GARDP hunt for new antibiotics
Pharmaforum
Eisai
Takeda
GARDP
antibiotics
R&D
Flag link:
Experimental treatment appears effective against gonorrhea in small study
Experimental treatment appears effective against gonorrhea in small study
Stat
gonorrhea
antibiotics
zoliflodacin
Entasis
Flag link:
Paratek caps 20-year R&D journey with FDA OK for its broad spectrum antibiotic — time to talk launch
Paratek caps 20-year R&D journey with FDA OK for its broad spectrum antibiotic — time to talk launch
Endpoints
antibiotics
FDA
R&D
Paratek
Nuzyra
Flag link:
MicuRx Recieves Fast Track and QIDP Designations for MRSA Antiobiotics
MicuRx Recieves Fast Track and QIDP Designations for MRSA Antiobiotics
CP WIre
MicuRx Pharmaceuticals
MRX-1
contezolid
contezolid acefosamil
antibiotics
MRSA
Flag link:
MicuRx Recieves Fast Track and QIDP Designations for MRSA Antiobiotics
MicuRx Pharmaceuticals
MRX-1
contezolid
contezolid acefosamil
antibiotics
MRSA
Flag link:
Boehringer Ingelheim and Tsinghua University Collaborate to Harness the Immune System to Better Fight Infectious Diseases
Boehringer Ingelheim and Tsinghua University Collaborate to Harness the Immune System to Better Fight Infectious Diseases
CP Wire
antibiotics
Boehringer Ingelheim
drug development
Flag link:
Tetraphase Pharma’s Antibiotic Wins FDA Approval for Gut Infections
Tetraphase Pharma’s Antibiotic Wins FDA Approval for Gut Infections
Xconomy
Tetraphase Pharmaceuticals
Xerava
FDA
antibiotics
cIAI
complicated intra-abdominal infections
Flag link:
Paratek clears one last big hurdle on the way to an FDA marketing decision for antibiotic
Paratek clears one last big hurdle on the way to an FDA marketing decision for antibiotic
Endpoints
Paratek
antibiotics
omadacycline
FDA
advisory panels
Flag link:
Paratek antibiotic not inferior to current treatments: FDA staff
Paratek antibiotic not inferior to current treatments: FDA staff
Reuters
Paratek
antibiotics
FDA
aminomethylcyclines
Flag link:
Urgent care centers often prescribe unnecessary antibiotics
Urgent care centers often prescribe unnecessary antibiotics
Reuters
antibiotics
antibiotic resistance
urgent care
physicians
Flag link:
Taking on biodefense threats, antibiotics maker Spero inks $54M in government deals
Taking on biodefense threats, antibiotics maker Spero inks $54M in government deals
Endpoints
Spero
antibiotics
biodefense drugs
defense contracts
Flag link:
Novartis joins the Big Pharma exodus out of antibiotics, dumping research, cutting 140 and out-licensing programs
Novartis joins the Big Pharma exodus out of antibiotics, dumping research, cutting 140 and out-licensing programs
Endpoints
Novartis
R&D
antibiotics
antivirals
layoffs
Flag link:
As drug resistance grows, combining antibiotics could turn up new treatments
As drug resistance grows, combining antibiotics could turn up new treatments
Stat
antibiotics
antibiotic resistance
drug development
Flag link:
It's a good news, bad news FDA approval for Achaogen's powerful antibiotic Zemdri
It's a good news, bad news FDA approval for Achaogen's powerful antibiotic Zemdri
Fierce Pharma
Achaogen
FDA
Zemdri
antibiotics
UTIs
Flag link:

Pages